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ABSTRACT 
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Despite the discovery of the oxygen-sensitive regulation of HIF? by the von 
Hippel-Lindau protein (VHL), the mechanisms underlying the complex genotype–
phenotype correlations in VHL disease remain unknown. Some germline VHL 
mutations cause familial pheochromocytoma and encode proteins that preserve 
their ability to downregulate HIF??? While type 1, 2A and 2B VHL mutants are 
defective in regulating HIF?, type 2C mutants encode proteins that preserve their 
ability to downregulate HIF???Here we identified a novel oxygen-sensitive function 
of VHL that is abolished by VHL type 2C mutations. We found that BIM-EL, a 
pro-apoptotic BH3-only protein, is hydroxylated by EglN3 and subsequently 
bound by VHL. VHL mutants fail to bind hydroxylated BIM-EL, regardless of 
whether they have the ability to bind hydroxylated HIF? or not. VHL binding 
inhibits BIM-EL phosphorylation by ERK kinase on serine 69. This causes BIM-
EL to escape from proteasomal degradation, allowing it to enhance EglN3-
induced apoptosis. BIM-EL was rapidly degraded in cells lacking wild-type VHL 
or in which EglN3 was inactivated genetically or by lack of oxygen, leading to 
enhanced cell survival and chemotherapy-resistance. Combination therapy using 
ERK inhibitors, however, resensitizes VHL- and EglN3-deficient cells that are 
otherwise cisplatin resistant. 
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SIGNIFICANCE 
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Different mutations of the VHL tumor suppressor gene cause different subtypes 
of the von Hippel–Lindau hereditary cancer syndrome. Dysregulation of VHL’s 
canonical substrate, HIF?? cannot fully explain the complex genotype-phenotype 
manifestation within the VHL disease. Here we describe a new oxygen-sensitive 
function of VHL that regulates hydroxylated BIM-EL protein stability during 
developmental apoptosis. We show type 2C VHL mutants, which cause 
pheochromocytoma and paraganglioma despite repressing HIF?? destabilize 
Bim-EL?. Other genetic mutations linked to paraganglioma, similar to loss of Bim-
EL, protect from apoptosis upon NGF withdrawal. It is therefore likely that 
dysregulation of BIM-EL contributes to the pathogenesis of VHL-related 
pheochromocytoma. Furthermore, loss of BIM-EL expression can lead to 
chemotherapy-resistance in other VHL related neoplasms and renders ccRCC 
cells insensitive to cisplatinum. 
 
\body 
INTRODUCTION 
Von Hippel-Lindau Disease (VHL) is caused by germline mutations of the VHL 
gene and predisposes to a variety of tumors including haemangioblastoma (HB) 
of the retina and nervous system, clear renal cell carcinoma (ccRCC; the most 
common form of kidney cancer) and tumors of sympathoadrenal origin, such as 
pheochromocytoma/paraganglioma (PCC/PGL) (1). HIF? activation is necessary 
and sufficient for many of the manifestations of VHL loss of function.  For 
example, HIF? deregulation appears to play a causal role in VHL-defective 
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ccRCC and in VHL-defective HB (1).  Nonetheless, a number of other 
biochemical functions have been ascribed to pVHL, including binding to 
fibronectin, collagen, atypical PKC, and AKT (2-6). Different VHL germline 
mutations cause different organ-specific cancer risks in VHL disease (1). Type 1 
VHL disease is defined as ccRCC and HB with low risk of PCC/PGL and is 
associated with disruptive mutations and gross deletions in VHL leading to very 
high HIF? expression. Type 2, which is predominantly associated 
with VHL missense mutations, is defined by the occurrence of PCC/PGL, either 
alone (type 2C) or in combination with hemangioblastomas (type 2A) or with 
hemangioblastomas and RCCs (type 2B).  Some Type 2C mutants retain the 
ability to suppress HIF? (7, 8). This suggest that PCC/PGL in type 2C VHL 
disease are not caused by HIF? activation and thus VHL type 2C mutants would 
be a powerful tool to identify HIF?-independent VHL functions.  
We previously reported that genetic alterations, including VHL alterations, 
linked to familial PCC/PGL may act by decreasing the activity of a 2-
oxoglutarate-dependent oxygenase, EglN3, thereby reducing apoptosis of neural 
crest cells during development (9). Furthermore, EglN3-induced apoptosis 
requires its hydroxylase activity, but is independent of its role in suppressing 
HIF??(9). Using an unbiased genome-wide shRNA screen we identified the 
candidate 1p36 tumor suppressor KIF1Bβ, which is required for EglN3-
dependent apoptosis and we and others identified loss-of-function germline 
KIF1B? mutations in subsets of PCC/PGL and neuroblastomas (10-12). However, 
EglN3 does not appear to hydroxylate KIF1Bβ, which led us to search for EglN3 
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pro-apoptotic substrates. Here we identified the pro-apoptotic BH3-only protein 
BIM-EL as a direct EglN3 hydroxylation substrate. BIM-EL represents an isoform 
of the BCL2L11 gene.  The three major BIM isoforms are BIM-EL, BIM-L and 
BIM-S and all contain a BH3 domain, but have different pro-apoptotic 
potencies. We found hydroxylation of BIM-EL, but not BIM-L and BIM-S, enables 
direct VHL binding, that masks the phosphorylation site that is critical for BIM-EL 
protein degradation. Importantly, VHL recognition of hydroxylated BIM-EL is 
abolished by VHL type 2C mutations, including type 2C mutations that do not 
result in HIF? stabilization. Furthermore, reintroduction of wild-type VHL, but not 
type 2C VHL mutants, into VHL-/- cells restores the ability of EglN3 to induce 
apoptosis. These studies suggest that PCC/PGLs linked to VHL mutations are 
caused by defects in EglN3-induced apoptosis because of a failure to stabilize 
BIM-EL. 
 
RESULTS 
EglN3-induced apoptosis and regulation of BIM-EL is hydroxylation and 
VHL-dependent.  
We previously demonstrated that EglN3 activity is required for apoptosis when 
sympathetic neurons are deprived of nerve growth factor (NGF) in vitro (9, 10).  
We also confirmed that the superior cervical ganglia (SCG), which are composed 
of such neurons, from post-natal day 1 (P1) mice lacking EglN3 are enlarged 
compared to their wild-type littermates (Fig. 1A), in keeping with a prior study 
(13). The proapoptotic BCL-2 family member BIM-EL is critical for neuronal 
apoptosis (14) and hypoxia’s ability to suppress apoptosis after NGF withdrawal 
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involves suppression of BIM-EL (15).  Thus, we investigated if EglN3 
hydroxylation activity can induce BIM-EL.  
We observed that BIM-EL protein was dramatically reduced in EglN3-/- 
SCG and primary mouse embryonic fibroblasts (MEFs) compared to littermate 
control EglN3+/+ SCG and MEFs, respectively (Fig. 1B,C) and in neuroblastoma 
cells in which EglN3 was downregulated with shRNA (Fig. 1D). To understand if 
BIM-EL protein levels are regulated by EglN3 hydroxylation activity, we made 
adenoviruses encoding wild-type (WT) EglN3 or a catalytic-dead EglN3 mutant 
(H196A). BIM-EL levels were restored in EglN3-/- MEFs infected with Ad-EglN3-
WT, but not Ad-EglN3-H196A (Fig. 1E). Thus, EglN3 hydroxylation activity 
regulates BIM-EL expression.  
To investigate if this effect on BIM-EL was specific to EglN3 amongst the 
three EglN paralogs, we specifically silenced EglN1, EglN2, or EglN3 in HeLa 
cervical carcinoma cells using siRNAs (Fig. 1F and SI Appendix, Fig. S2A). BIM-
EL protein levels were reduced by silencing EglN3, and to a much lesser extent 
by EGLN2, but not by silencing EGLN1. Conversely, silencing EglN1 caused the 
greatest effect on HIF1?, consistent with earlier studies (16), whereas silencing 
EglN3 had no measureable effect on HIF1?, suggesting specificity of function 
within the EGLN family members. 
 We next overexpressed EglN3 in cell lines of sympathoadrenal (PC12, rat) 
(SI Appendix, Fig. S1A) or neuronal origins (U87, human) (Fig. 1G) using the 
adenovirus described above. In these cells, wild-type, but not catalytic-dead, 
EglN3, induced BIM-EL and apoptosis as measured by caspase 3 cleavage and 
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crystal violet staining. Moreover, the effect of EglN3 on BIM-EL was blocked 
under anoxic conditions and by the hydroxylase inhibitors DMOG and FG0041 in 
EglN3 primary MEFs (Fig. 1H). 
To address whether induction of BIM-EL is necessary for EglN3 to induce 
cell death, we silenced BIM-EL with two independent shRNA’s in U87 cells (Fig. 
1I) or using two independent siRNAs in PC12 cells (SI Appendix, Fig. S1B). 
Silencing BIM-EL protected against EglN3-induced apoptosis as measured by 
crystal violet staining, caspase 3 cleavage, and nuclear fragmentation. 
Since we observed that BIM-EL protein abundance is dependent on EglN3 
hydroxylase activity, we investigated if this observation is VHL-dependent. Cre-
mediated deletion of VHL in MEFs homozygous for a floxed VHL allele robustly 
decreased BIM-EL protein levels (Fig. 2A), reminiscent of the loss of BIM-EL in 
EglN3-/- MEFs. Furthermore, reintroducing HA-VHL (WT) into VHL-deficient 
RCC cells (786-O) restored BIM-EL protein expression (Fig. 2B) unless EglN3 
was inactivated with an effective shRNA (Fig. 2C) or by anoxia (Fig. 2D).   
Type 2C VHL mutants predispose to PCC/PGL without grossly 
deregulating HIF??(7). We therefore asked if VHL type 2C mutations are loss of 
function with respect to BIM-EL regulation and if this is reflected in VHL defective 
human PCC/PGL. Compared to wild-type HA-VHL, type 2C HA-VHL (L188V and 
R64P) were clearly defective with respect to BIM-EL induction when reintroduced 
into 786-O cells despite their ability to repress HIF2? (Fig. 2E). Moreover, VHL-/- 
786-O cells were resistant to EglN3-induced apoptosis (Fig. 2F). Importantly, 
reintroduction of wild-type VHL, but not the type 2C VHL mutant L188V, rescued 
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the ability of EglN3 to induce apoptosis as measured by crystal violet staining 
and caspase 3 cleavage (Fig. 2F). Consistent with the data in Fig. 1I, silencing 
BIM-EL also prevented EglN3-induced apoptosis in the context of 786-O cells 
(Fig. 2G).  EglN3 expression also caused some growth inhibition seen in crystal 
violet staining two weeks’ post infection in VHL-/- and mutant cells, consistent 
with previous reports that EgLN3 can suppress cell proliferation (17, 18). 
Similarly to 786-O cells, VHL knockdown in rat PC12 pheochromocytoma cells 
decreased BIM-EL levels (Fig. 2H) and protected against EglN3 induced 
apoptosis (Fig 2I). Reintroduction of human HA-VHL WT however, but not VHL 
2C-L188V, restored BIM-EL expression and EglN3 induced apoptosis, 
suggesting that EglN3’s apoptotic function is linked to VHL type 2C PCC/PGL 
pathogenesis .  
Thus, we assayed BIM-EL protein level in a panel of human primary 
PCC/PGL tumors that were sequenced for PCC/PGL-susceptibility genes, 
including VHL, and analyzed for 1p36 deletion (12). Normal human adrenal 
glands were included as controls (Fig. 2J and SI Appendix, Fig. S2B). We 
observed low BIM-EL expression only in the PCC/PGL tumors carrying VHL 
mutations and not in other PCC/PGL, supporting our cell culture findings that 
BIM-EL protein regulation is VHL-dependent. 
 
EglN3 hydroxylates BIM-EL at the Proline67/70 residues enabling interaction 
with wild-type VHL but not VHL type 2C-disease mutants. 
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To test whether prolyl-hydroxylation of BIM-EL by EglN3 is responsible for the 
VHL-dependent regulation of BIM-EL abundance, we first performed EglN3 
binding studies with BIM-EL using glutathione S-transferase (GST) pull-down 
assays.  GST-BIM-EL bound to 35S-labeled EglN3 produced by in vitro translation 
(IVT), but not to 35S-EglN1 or 35S-EglN2 (Fig. 3A and SI Appendix, Fig. S3A). No 
interaction was observed between 35S-EglN3 and GST-BIM-L, a shorter BIM 
variant missing 116 amino acids generated by alternative splicing (Fig. 3A, and 
SI Appendix, Fig. S3A). Thus, we investigated if BIM-EL could be hydroxylated 
by EglN3 and subsequently recognized by VHL. In vitro translated HA-BIM-EL 
and HA-BIM-L were HA-immunoprecipitated and used in EglN3 hydroxylation 
assays. HA-HIF1? was tested in parallel as a positive control. HA-BIM-EL and 
HIF1? but not HA-BIM-L, captured 35S-labeled VHL after incubation with EglN3 
(Fig. 3B), suggesting that EglN3 hydroxylates proline(s) within the amino acid 
region that is missing in BIM-L. EglN3 enzymatic activity was required for VHL 
binding, because BIM-EL subjected to hydroxylation reactions using EglN3 
catalytic-dead mutant (H196A) failed to capture 35S-VHL (SI Appendix, Fig. S3B). 
Furthermore, a pan-hydroxyproline antibody immunoprecipitated an apoptosis-
defective HA-BIM-EL apoptotic variant (BIM-EL-∆BH3) from 293 cells (the 
apoptotic-defective variant was used to allow stable expression) that 
exogenously EglN3 unless the EglN3 was catalytically inactive or the cells were 
treated with DMOG (Fig. 3C and SI Appendix, Fig. S3C). 
Next, we generated different peptides within the 116-aa region within BIM-
EL to narrow the EglN3-binding domain and potential hydroxylation site (Fig. 3D). 
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We observed 35S-EglN3 binding to biotinylated BIM-EL peptide corresponding to 
residues 65–89 (BIM-EL 65-89), but not to BIM-EL peptide corresponding to 
residues 55–79 (SI Appendix, Fig. S3D). However, despite EglN3 binding, we 
could not detect binding of VHL to BIM-EL 65-89 after incubation with EglN3 (SI 
Appendix, Fig. S3E). This prompted us to generate a longer peptide (40 aa), 
corresponding to BIM-EL-residues  57–96. This longer biotinylated BIM-EL 
peptide captured 35S-VHL after the EglN3 hydroxylation reaction, similar to that of 
the biotinylated HIF1??peptide residues 556–575 (SI Appendix, Fig. S3E). Next, 
we tested if BIM-EL hydroxylation is a specific function of EglN3 amongst the 
EglN paralogs.  Incubation of the BIM-EL-peptide-57-96 with EglN3, but not with 
EglN1 or EglN2, promoted the capture of 35S-VHL (Fig. 3E), consistent with our 
earlier observations that regulation of BIM-EL abundance (Fig. 1F) and binding to 
BIM-EL (Fig. 3A) is a distinguishing feature of EglN3. In contrast, and as 
previously reported (19), the HIF1? peptide was hydroxylated in vitro by all three 
EglN family members (Fig. 3E). Hydroxylation of the BIM-EL-peptide-57-96 was 
confirmed by LC-MS/MS analysis (Fig. 3F and SI Appendix, Fig. S3F-I). MS 
confirmed that EglN3, but not the catalytic-dead mutant, hydroxylated proline 67 
and proline 70 (Fig. 3F and SI Appendix, Fig. S3F). We detected mono-
hydroxylated peptide on either proline 67 (SI Appendix, Fig. S3G) or proline 70 
(SI Appendix, Fig. S3H) as well as di-hydroxylated peptides on proline 67 and 70 
(Fig. 3F). In addition to proline hydroxylation, we detected oxidation of the biotin 
residue, which is a common artefact, in hydroxylation reactions containing wild-
type EglN3 or catalytic-dead EglN3 (20). The detected intensity of each proline 
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hydroxylated peptide was quantified and normalized to the non-hydroxylated 
peptide (Fig. 3G). Peptides mono-hydroxylated on proline 67 or proline 70 co-
eluted in the chromatography, which prevented us from quantifying the 
hydroxylation of either site individually. To understand the importance of mono- 
or di-hydroxylation of the respective proline residues for VHL binding, we 
synthesized BIM-EL-57-96 peptides with the  proline to alanine substitutions: 
P60A, P63A, P66A, P67A, P70A, P67/70A, and P66/67/70A, and measured their 
hydroxylation by EglN3 using the 35S-VHL capture assay (Fig. 3H). The P60A 
and P63A proline substitutions did not alter hydroxylation relative to the wild-type 
peptide.  In contrast, the P66A, P67A and P70A substitutions significantly 
impaired 35S-VHL capture and the triple substitutions P66/67/70A completely 
abolished 35S-VHL recognition (Fig. 3H). It is possible that the mutated P67A 
peptide generates some substrate recognition for proline 66. Jumping to 
neighboring lower affinity sites has been previously observed in in vitro 
enzymatic assays of other posttranslational modifications (21). In a reciprocal 
experiment, we synthesized BIM-EL-57-96 peptides in which proline 67(P-OH-
67), proline 70 (P-OH-70), or both (P-OH-67/70) were hydroxylated (Fig. 3I). As 
expected, all three hydroxylated peptides could, similar to hydroxylated 
HIF1?  (556–575), captured 35S-pVHL (Fig. 3J). In contrast, non-
hydroxylated BIM-EL peptide (BIM-EL-WT) did not capture 35S-pVHL.  
Our finding that BIM-EL expression can be restored by wild-type VHL, but 
not type 2C VHL mutants (Fig. 2E), suggested that the latter cannot recognize 
hydroxylated BIM-EL.  Indeed, type 2C VHL mutants bound to a hydroxylated 
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HIF1??peptide, but failed to bind hydroxylated BIM-EL peptide (P-OH-67/70) (Fig. 
4A). Type 1 and type 2A/B VHL mutants also failed to recognize hydroxylated 
BIM-EL (Fig. 4A). We complimented these studies by expressing either wild-type 
HA-pVHL (WT) or the corresponding type 1or 2A/B/C VHL mutants in 786-O cells 
and performing pulldown assays with immobilized BIM-EL or HIF1???peptides. As 
expected, wild-type VHL bound to the di-hydroxy-BIM-EL peptide (P-OH-67/70), 
but not to a non-hydroxylated BIM-EL peptide or scrambled peptide (Fig. 4B). 
Consistent with our findings in Fig. 4A, the type 2C VHL mutants bound to the 
hydroxylated HIF1? peptide, but not the hydroxylated BIM-EL peptide, while the 
type 1 and type 2A/B were defective for both (Fig. 4C). Consistent with these 
findings, only wild-type VHL fully restored BIM-EL levels when introduced into 
786-O cells (Fig. 4D). In contrast, but in keeping with prior studies, both type 2C 
VHL mutants suppressed HIF? (Fig. 4D).   
 
VHL-mediated regulation of BIM-EL protein stability is dependent on EglN3 
enzymatic activity. 
VHL stabilizes BIM-EL in RCC cells, but the mechanism is unknown (22). Since 
we observed that VHL binds to hydroxylated BIM-EL, we asked if this physical 
association stabilizes BIM-EL despite VHL’s well-established role as a 
component of an E3 ubiquitin ligase.  The BIM-EL sites hydroxylated by EglN3 
(P67 and P70) are near a critical serine residue (S69) that dictates BIM-EL 
proteasomal degradation upon ERK phosphorylation (23). Thus, we 
hypothesized that binding of VHL to hydroxy-P67/P70 masks the S69 
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phosphorylation site and thus prevents the proteasomal degradation of BIM-EL. 
First, we used the proteasome inhibitor MG132 to determine if the loss of BIM-EL 
in EglN3-KO (-/-) primary MEFs was due to proteasomal degradation. MG132 
increased BIM-EL protein abundance in EglN3-KO (-/-) MEFs to the level of 
EglN3 WT (+/+) MEFs (Fig. 5A). A HIF1? immunoblot served as a positive 
control to assure MG132 activity. Likewise, MG132 treatment of VHL-/- cells 
(786-O) restored BIM-EL levels (Fig. 5B), providing evidence that loss of either 
EglN3 or VHL accelerates BIM-EL proteasomal degradation. Importantly, 
phosphorylation of BIM-EL on the critical Ser69 residue required for protein 
turnover was markedly increased in both EglN3-/- MEFs (Fig. 5C and SI 
Appendix, Fig. S4A) and VHL-/- MEFs (Fig. 5D and SI Appendix, Fig. S4B), 
consistent with the idea that EglN3 and VHL block Ser69 phosphorylation.  
Next, we investigated if VHL interacts with endogenous BIM-EL in 786-O 
cells expressing HA-VHL(WT)  and if this was dependent on EglN3. BIM-EL was 
readily detected in anti-HA immunoprecipitates of cells expressing HA-VHL 
unless EglN3 was downregulated with an effective shRNA (Fig. 5E). Furthermore, 
BIM-EL co-immunoprecipitated only with wild-type VHL, but not VHL type 2C 
mutant L188V (Fig. 5F). To test if VHL binding to hydroxylated BIM-EL might 
block Ser69 phosphorylation, we performed in vitro ERK kinase assays. ERK-
kinase activity was first measured using a wild-type BIM-EL-peptide (WT) or a 
hydroxylated BIM-EL-peptide (BIM-EL-P-OH-67/70) as ERK substrates.  Both 
peptides were similarly phosphorylated by ERK-kinase in vitro as measured by 
phospho-BIM-EL(Ser69) immunoblot analysis (Fig. 5G). However, preincubation 
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with GST-VHL prevented the hydroxylated BIM-EL peptide (P-OH-67/70) from 
being phosphorylated by ERK (Fig. 5H).  
To ask if EglN3 and VHL stabilizes BIM-EL protein, we treated 786-O cells 
with the protein synthesis inhibitor cycloheximide. The half-life of BIM-EL was 
shorter in VHL-/- 786-O cells compared to wild-type VHL (Fig. 5I,J). Similarly, the 
half-life of BIM-EL was shorter in EglN3-KO MEFs, accompanied with increased 
phosphorylation on Ser69, compared to wild-type MEFs (Fig. 5K,L). These 
results demonstrate that VHL and EglN3 specifically stabilize BIM-EL in cells by 
preventing Ser69 phosphorylation. In accord with these data, we show that 
exogenous expression of the apoptosis-defective mutant of BIM-EL (HA-BIM-
EL?BH3) harboring the serine 69 to alanine substitution (S69A) was stabilized in 
786-O cells in the absence of VHL (Fig. 5M). Furthermore, exogenous BIM-EL 
wild-type (HA-BIM-EL?BH3) protein was stabilized in VHL null cells (786-O) that 
were treated with different ERK kinase inhibitors (Fig. 5N).  
Thus, we conclude that binding of VHL to hydroxylated BIM-EL prevents 
BIM-EL-Ser69 phosphorylation and degron recognition and thus allows BIM-EL 
to escape from proteasomal degradation (SI Appendix, Fig. S4C). 
 
Loss of EglN3 or VHL causes cisplatin drug resistance.  
BIM protein degradation has been linked to cisplatin resistance in cancer therapy 
(24). ccRCC cells derived from renal epithelial cells, which are normally 
cisplatinum sensitive, and yet ccRCC and other VHL-associated neoplasms are 
generally resistant to chemotherapy, including cisplatinum.   Thus, we 
investigated if loss of EglN3 or VHL can likewise contribute to cisplatin resistance. 
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Silencing of EglN3 has been recently described in high grade glioma (25) and 
VHL loss is well characterized in ccRCC (1). Therefore, we explored cisplatin 
responsiveness in isogenic 786-O (VHL+/+ and VHL-/-) ccRCC cells, in 
neuroblastoma cells (SK-N-FI) that express EglN3 and VHL, and in primary (JM3, 
JM2, KS1, KS4, KS8, G3) and permanent (U87) glioblastoma cell lines (GBM) in 
which EglN3 mRNA levels were determined by RNA Seq (26). (Fig. 6A). We 
identified only one human primary GBM cell line (JM3) expressing EglN3. In 
addition, high EglN3 expression was observed in human mature astrocytes 
compared to normal other human tissues (SI Appendix, Fig. S5A) (24), while 
EglN3 expression in the remaining primary GBM cultures were either significantly 
lower or undetectable altogether (Fig. 6A). We assessed the response of JM3 
(EglN3-positive) and KS4 (EglN3-negative) cells to address their response to 
cisplatin. Cisplatin treatment caused a robust induction of endogenous EGLN3 
accompanied by the induction of BIM-EL and caspase 3 cleavage in JM3 cells, 
but not the KS4 cells (Fig. 6B). To understand if cisplatin resistance was caused 
by the lack of EglN3 expression, we reintroduced EglN3 into KS4 cells using 
lentivirus encoding wild-type EglN3 or catalytic dead mutant (H196A). Stable re-
introduction of EglN3 wild-type, but not mutant, caused a marked increase of 
BIM-EL protein in KS4 cells, that was further induced by cisplatin, leading to 
sensitization of these cells to cisplatin-induced apoptosis (Fig. 6C). Although 
catalytic-dead EglN3 failed to rescue BIM-EL protein expression in untreated 
cells, it did cause a modest induction of BIM-EL in the presence of cisplatin. The 
significance of this finding is not clear, but could reflect a hydroxylase-
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independent function of EglN3 that is unmasked by cisplatin (Fig. 6C). 
Nonetheless, the cells expressing EglN3 catalytic-dead mutant remained 
resistant to cisplatin induced apoptosis (Fig. 6C).  
Similarly, lowering EglN3 levels in JM3 cells (SI Appendix, Fig. S5B) or 
SK-N-FI cells (SI Appendix, Fig. S5C) with an effective shRNA lowered BIM-EL 
levels and conferred cisplatin resistance (SI Appendix, Fig. S5C). Furthermore, 
reintroducing HA-VHL into VHL-/-  786-O cells restored the ability of cisplatin to 
induce BIM-EL and apoptosis in these cells (Fig. 6D).  
Next, we tested if EglN3-null or VHL-null cells can be sensitized to 
cisplatin -induced apoptosis in combination with ERK inhibitors. BIM-EL 
expression was restored to that of EglN3 wild-type expressing KS4 glioma cells 
24 hrs after treatment with various ERK inhibitors (SI Appendix, Fig. S5D). 
Despite BIM-EL induction in EglN3-null or EglN3-H196A mutant cells, ERK 
inhibitor alone caused only significant apoptosis in EglN3 wild-type (WT) 
expressing cells (Fig. 6E,F). Combined treatment of cisplatin and ERK inhibitor 
caused apoptosis irrespective of EglN3 status (Fig. 6E,F) without showing any 
further increase of BIM-EL protein compared to ERK inhibitor alone. Similarly, 
treatment of VHL null cells with an ERK inhibitor alone did not cause apoptosis, 
despite BIM-EL induction (Fig. 6G,H), but did so when combined with cisplatin 
(Fig. 6G and SI Appendix, Fig. S5E). Thus, highly efficient killing by the BIM-EL 
induced by ERK inhibitors in cells lacking EglN3 or VHL requires one or more 
collateral signals that can be provided by cisplatin.   
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DISCUSSION 
The canonical function of VHL is to ubiquitinate hydroxylated HIF? for 
proteasomal degradation. HIF? deregulation can cause PCC and PGL, as 
evidenced by gain of function HIF2??and loss of function EglN1 mutations in rare 
familial cases. However, the mechanisms underlying the complex genotype–
phenotype correlations in VHL disease cannot be explained by HIF? regulation. 
VHL type 2C mutations are not related to HIF? activation and preserve their 
ability to downregulate HIF? (7, 8). Here we identified a novel oxygen sensitive 
function of pVHL that is abolished by VHL type 2C mutations. We identified BIM-
EL as a direct EglN3 hydroxylation substrate and that hydroxylated BIM-EL is 
bound and stabilized by binding to VHL, but not by VHL type 2C mutants. BIM-EL 
hydroxylation on P67 and P70 is in near proximity to the critical serine 69, which 
dictates BIM-EL proteasomal degradation upon ERK phosphorylation (23). We 
observed that pVHL binds to hydroxylated BIM-EL at P67/P70 and prevents ERK 
phosphorylation on serine 69, leading to BIM-EL protein stabilization. Indeed, low 
BIM-EL expression in the PCC/PGL tumors carrying VHL mutations confirms that 
BIM-EL protein regulation is VHL-dependent.  
 
We previously reported that EGLN3 hydroxylase activity is linked to PCC 
pathogenesis through regulation of apoptosis during sympatho-adrenal 
development, which is independent of HIF? hydroxylation (9). Here we identified 
that VHL loss causes resistance to EGLN3-induced apoptosis and that this can 
be restored by wildtype VHL, but not by VHL type 2C mutants.  Furthermore, we 
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found that EGLN3-induced apoptosis requires hydroxylation of BIM-EL, which in 
turn allows for VHL recognition of the protein, thus leading to BIM-EL protein 
stabilization. Bim deletion has been reported to cause protection against 
developmental and induced neuronal apoptosis, in both, central and peripheral 
neuron populations (14). Furthermore, inhibition of NGF deprivation–induced 
death by low oxygen levels during sympathetic neuronal development involves 
suppression of BIM-EL (15). By identifying BIM-EL as a direct EGLN3 
hydroxylation substrate, we provide the missing mechanistic link between VHL 
type 2C PCC-mutations, EGLN3 hydroxylase activity, and escape from apoptosis 
during sympatho-adrenal development.  
Thus, our work provides insights as for why VHL type 2C mutations 
contribute to PCC/PGL pathogenesis. We identified a biochemical activity that is 
lost by Type 2C pVHL mutants, leading to a loss of BIM-EL. Moreover, this 
biochemical activity affects neuronal apoptosis after NGF withdrawal, as do many 
of the other PCC/PGL-associated genes. Therefore, the law of parsimony 
suggests that dysregulation of BIM-EL contributes to the pathogenesis of PGLs 
caused by VHL mutations (including Type 2C mutations). Nonetheless, Type 2C 
mutants have also been shown to be defective with respect to other biochemical 
properties, including fibronectin and collagen binding (2-4). It is possible that 
these other biochemical properties are relevant to PGL as well. 
Why germline type 1 VHL mutation (deleterious mutants) seldom causes 
PCC/PGL despite BIM-EL reduction has not been addressed in this work. 
However, we predict that complete loss of VHL during sympathoadrenal 
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development is not tolerated and thus does not result in PCC/PGL outcome. This 
argument is in line with observations in VHL conditional knockout studies in mice 
(TH-cre) which show that loss of VHL during development results in the 
disappearance of catecholaminergic cells (27), in contrast to conditional TH-
EglN1KO mice that causes hyperplasia in the carotid body (28). This suggests 
that unknown VHL functions are required for the formation of the 
sympathoadrenal cell lineage and therefore complete loss of VHL (type 1) might 
not be permissive in PCC/PGL pathogenesis. In contrast, in missense mutated 
VHL cells, reduction of BIM-EL protein might not impair the formation of the 
sympathoadrenal lineage. Instead it provides a mechanism to escape 
developmental apoptosis independent of HIF? regulation contributing to 
PCC/PGL. Our observation that all VHL mutated PCC/PGL tumors show reduced 
BIM-EL expression in contrast to other non VHL mutated PCC/PGL tumors 
support this. However, that would not exclude other VHL substrates contributing 
to VHL related pheochromocytoma.  
 
Evading apoptosis is a hallmark of cancer. Every VHL mutation we have 
examined to date, whether type 1 and type 2, leads to loss of BIM-EL. It is 
therefore likely that loss of BIM-EL contributes to the pathogenesis of VHL-
related neoplasms other than paragangliomas, including ccRCC and 
hemangioblastoma, as well as their characteristic insensitivity to chemotherapy. 
In this regard, cisplatinum damages renal epithelial cells, leading to renal 
dysfunction, and yet is inactive against ccRCCs. We showed that loss of VHL, 
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and subsequent downregulation of BIM-EL, renders ccRCC cells insensitive to 
cisplatinum. Thus, we investigated further EglN3 role during cisplatinum 
response. Cisplatin treatment induced EGLN3 in VHL WT expressing cells, 
accompanied by BIM-EL induction and apoptosis, whereas EglN3-silenced 
neuroblastoma cells or VHL-null ccRCC cells were resistant. Re-introduction of 
wild type VHL, but not by type 2C VHL mutants in ccRCC cells restored 
sensitivity. We also studied resistance to cisplatin in high grade glioma cells, 
since EglN3 has been reported to be silenced during glioma progression (25). 
We observed that EglN3-silenced glioblastoma cells were cisplatin resistant, but 
sensitized upon re-introduction of wild-type EGLN3. In line with our observations, 
other studies also reported that EglN3 and BIM-EL are required for successful 
pro-apoptotic activity of various DNA damage–inducing chemotherapeutical 
agents (29, 30). By unraveling the precise molecular mechanism of BIM-EL 
stabilization by VHL and EglN3, we provide further insights into the 
chemoresistance that is typical of tumors lacking VHL or oxygen. Thus, 
restoration of BIM-EL protein expression by combination therapy using ERK 
inhibitors together with cisplatin might provide a promising approach for cancer 
therapy (SI Appendix, Fig. S5F). 
 
Methods 
 
Cell culture  
Human neuroblastoma cell line SK-N-FI and the rat pheochromocytoma cell line 
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PC12 were maintained as previously described (10). Human glioblastoma cell 
line U87 was maintained in DMEM (glucose 1g/L) containing 10% fetal bovine 
serum (FBS). Mouse embryonic fibroblasts (MEFs) and human RCC cell line 
(786-O) were cultured in DMEM (glucose 4,5g/L) containing 10% fetal bovine 
serum (FBS) in 5% CO2 at 37°C. The 786-0, SK-N-FI and PC12 cell lines were 
purchased from the American Tissue Culture Collection. VHLfl/fl immortalized 
MEF’s have been previously described (31),  containing a blasticidin resistance 
cassette and directed the expression of large T antigen K1 (K1 T antigen 
inactivate p53 but not pRB). Human primary glioblastoma cell cultures were 
established as previously described (26). 
 
EglN3 knockout mice 
Generation of the EglN3 mouse strain is described in (10). P1 Super cervical 
ganglia dissections of EglN3 pups are described in (32).  
 
Human tissue specimen 
PCC and abdominal PGL were collected from patients operated and diagnosed 
at the Karolinska University Hospital, Stockholm, Sweden, previously 
characterized for mutations in 14 proposed PCC/PGL susceptibility genes (12) 
(SI Appendix, Fig. S2). Four histologically confirmed normal adrenal glands from 
de-identified patients were included as controls. VHL mutations in sample 21, 25, 
96 and 108 have been previously described (12):  
Sample 21: Diagnosed with cerebellar hemangioblastoma and 
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pheochromocytoma the same year. Syndromic VHL patient with a germline VHL 
mutation c.217C>T p.Gln73X  (frameshift mutation resulting in truncated VHL , 
type 1). Please note: #21 has a truncating mutation. The risk of developing PCC 
in VHL type 1 patients is not zero, but lower than for type 2 patients. 
Sample 25: Diagnosed with PCC at age of 13 with normal epinephrine and 
norepinephrine levels with no evidence of metastasis or relapse and no 
additional tumors. Syndromic VHL patient with a germline VHL mutation: 
c.193T>G p.Ser65Ala, pos 3:10183724. 
Sample 96: Pheochromocytoma, trichoepithelioma eight years earlier (benign 
skin lesion). Apparently sporadic patient (no VHL syndrome) with a somatic VHL 
mutation. Mutations identified in sample 21: EGLN1 c.799G>A p.Glu267Lys 
+ SDHA c.223C>T p.Arg75X + VHL c.386T>C p.Leu129Pro  
Sample 108: Paraganglioma in 1998, basal cell carcinoma of the skin in 2013, 
follicular lymphoma in 2018. Apparently sporadic patient (no VHL syndrome) with 
a somatic VHL mutation: VHL c.593T>G p.Leu198Arg. 
 
Ethical Considerations 
Human samples (normal tissues, PCCs and PGLs) are covered both by an 
existing ethical approval (Drn 01-136, KI forskningsetikkommitté Nord). Human 
glioblastoma tissue specimens were collected via surgical resection under the 
ethical permit KI 2013/576-31, issued by the Ethical Review Board at Karolinska 
Institutet, in accordance with the declaration of Helsinki. All samples were 
obtained following an informed patient consent. Ethical permits for animal studies 
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were approved by the appropriate local and national authorities – 
Jordbruksverket, Sweden. 
 
Peptide pull-down assay  
Streptavidin beads were incubated with biotinylated peptides (synthesized by 
peptides&elephants GmbH) and rotated for 1hour at room temperature. 35S-VHL 
produced by IVT was captured as previously described (9). For pull down assays 
using VHL-expressing 786-O cells, conjugated streptavidin beads with 
biotinylated peptides were incubated with 786-0 cell lysate overnight at 4°C with 
rotation. Samples were then washed 4 times with immunoprecipitation wash 
buffer (0.5% NP-40, 150mM NaCl, 10mM Tris-HCl) and eluted with 30ul Laemmli 
buffer, boiled for 5 minutes and centrifuged at 8000xg for 30 seconds. Eluted 
supernatant was subjected to immunoblot analysis. 
 
Peptide hydroxylation and 35S-VHL binding assay 
FLAG-EGLN1/2/3 and VHL were produced by in vitro transcription /translation 
reactions (IVT) using TnT® T7 Quick Master Mix. 1ug BIM-EL and HIF1? 
biotinylated peptides were respectively conjugated with Streptavidin agarose 
beads in 1ml PBS at room temperature with rotation for 1h. The beads pellet was 
washed twice with PBS and once with hydroxylation buffer (40mM HEPES, 
ph7.4, 80mM KCl). The pellet was resuspended with 300ul hydroxylation reaction 
buffer supplemented with 100uM FeCL2, 2mM Ascorbate and 5mM 2-
oxolgutarate. 15ul IVT-synthesized EGLN was added to start the hydroxylation. 
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The hydroxylation reaction was processed for 2 hours at room temperature with 
rotation. 500ul EBC buffer was added to the reaction buffer to stop the 
hydroxylation and subsequently, 15ul IVT-synthesized S35 radioactive labeled 
VHL was added and this mixture was incubated overnight. Samples were 
centrifuged at 8000xg for 30 seconds and washed five times with wash buffer 
(0.5% NP-40, 150mM NaCl, 10mM Tris-HCl). Bound protein complexes were 
eluted with 30ul Laemmli buffer, boiled for 5 minutes and centrifuged at 8000xg 
for 30 seconds. Eluted supernatant was analyzed by immunoblot. 
 
Full length BIM-EL hydroxylation and S35VHL capture 
EglN3 WT, EglN3 mutant, 35S-VHL, BIM-EL were produced by in vitro 
transcription /translation reactions using TnT® T7 Quick Master Mix. In vitro 
translated BIM-EL was added to 300ul hydroxylation reaction buffer 
supplemented with 100uM FeCL2, 2mM Ascorbate and 5mM 2-oxolgutarate. 
15ul unprogrammed reticulocyte lysate, IVT-synthesized wild-type EglN3 or 
EglN3 mutant were added to start the hydroxylation. The hydroxylation reaction 
was processed for 2 hours at room temperature with rotation. 500ul EBC buffer 
was added to the reaction buffer to stop the hydroxylation. 15ul IVT-synthesized 
35S-VHL was added and this mixture was incubated for 2 hours at room 
temperature with rotation. BIM-EL was immunoprecipitated with anti-BIM-EL 
antibody overnight at 4°C with rotation and captured with protein G beads. The 
beads pellet was then washed five times with immunoprecipitation wash buffer 
(0.5% NP-40, 150mM NaCl, 10mM Tris-HCl). Bound protein complexes were 
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eluted with 30ul Laemmli buffer, boiled for 5 minutes and centrifuged at 8000xg 
for 30 seconds. Eluted supernatant was analyzed by immunoblot or S35 
autoradiography. 
 
Peptide hydroxylation assay and mass spectrometry analysis 
The hydroxylation assay with BIM-EL peptide was performed as described 
above. After hydroxylation, BIM-EL peptide conjugated beads were washed one 
time with hydroxylation buffer and three times with IP buffer without detergent. 
Samples were processed as described in (20). Biotinylated peptides were 
digested with chymotrypsin and directly analyzed by MS. Peptides were analyzed 
on a Q-Exactive mass spectrometer connected to an Ultimate Ultra3000 
chromatography system incorporating an autosampler (both Thermo Scientific). 
Proteolytic or synthesized peptides for each sample (5 μL) were applied to a 
home-made column (250-mm length, 75-μm inside diameter) (packed with 1.8 
μm UChrom C18) and separated using a 40-min reverse-phase acetonitrile 
gradient [5–70% (vol/vol) acetonitrile] with a 250-nL/min flow rate. The mass 
spectrometer was operated in positive ion mode with a capillary temperature of 
220 °C and a 2000 V potential applied to the column. Variable modifications were 
N-terminal biotin, N-terminal biotin hydroxylation and proline hydroxylation.  
 
Hydroxyproline Immunoprecipitation  
293FT cells were transfected with Flag-EglN3 and HA-BIM-EL apoptotic dead 
mutant (∆BH3). 40 hours after transfection, cells were treated with MG132 and/or 
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DMOG for 8hours as indicated. Cells were washed once in ice-cold PBS, lysed 
with EBC buffer (50mM Tris at pH 8.0, 120mM NaCl, 0.5% NP-40) containing 
protease inhibitors. Lysate was centrifuged at 14,000 × g for 20 minutes to 
remove cellular debris and the resulting supernatant was incubated with anti-
Hydroxyproline antibody (Abcam ab37067, batch: GR3215743-1) with overnight 
at 4°C. Samples were incubated for 4 hours with rotation at 4°C with 30ul Protein 
G agarose beads (sc-2002, SANTA CRUZ) (50% slurry) pre-washed twice with 
immunoprecipitation wash buffer (0.5% NP-40, 150mM NaCl, 10mM Tris-HCl). 
Samples were centrifuged at 8000xg for 30 seconds and washed five times with 
wash buffer (0.5% NP-40, 150mM NaCl, 10mM Tris-HCl). Bound protein 
complexes were eluted with 30ul Laemmli buffer, boiled for 5 minutes and 
centrifuged at 8000xg for 30 seconds. Eluted supernatant was analyzed by BIM-
EL immunoblot. 
 
Expression Plasmids, shRNA and siRNA’s 
pcDNA3 Flag-EglN3, Flag-H196A-mutant and pcDNA3-VHL including 
VHL-missense mutations are described previously (9). pcDNA3 HA-BIM-EL 
(mouse) and pcDNA3 HA-BIM-EL apoptotic mutant (ratBIM-EL∆BH3) were kind 
gifts from Stanley J. Korsmeyer, Dana-Farber Cancer Institute, USA. ratBIM-
EL∆BH3 was a mutation in the BH3 domain: L150RRIGDEFN158 mutated to 
A150RRIAAEFN158. Amino acid numbering refers to the rat Bim-EL sequence. 
ratBIM-EL∆BH3_S65A mutant was made using a site-directed mutagenesis kit 
(Aligent). Rat BIM-EL serine 65 residue correspond to human BIM-EL serine 69 
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residue. GST-BIM-EL and GST-BIM-L were kind gifts from S. Cook lab, 
Babraham Institute, Cambridge, UK. Lentivirus encoding FLAG-EglN3 and 
FLAG-EglN3-H196A was generated in 293FT cells as previously described (10). 
siRNAs targeting EglN1, EglN2 or EglN3 have been previously described and 
validated (34). Lentivirus encoding shRNAs targeting BIM and EglN3 were 
generated using the pLKO.1 plasmid using the following sequences: human BIM-
EL#54 5'-
CCGGAGCCGAAGACCACCCACGAATCTCGAGATTCGTGGGTGGTCTTCGG
CTTTTTT-3'; human BIM-EL#77 5'-CCGGGACCACCCAC 
GAATGGTTATCCTCGAGGATAACCATTCGTGGGTGGTCTTTTTG-3'; human 
EglN3 5'-CCGGGTTCTTCTGGTCAGATCGTAGCTCGAGCTACGATCTGAC 
CAGAAGAACTTTTTG-3'. 
 
P-ERK kinase activity assay  
1ug biotinylated hydroxylated BIM-EL-peptides were conjugated with Streptavidin 
agarose beads in 1ml PBS at room temperature with rotation for 1h. The beads 
pellet was washed three times with PBS and resuspended with 500ul PBS 
supplemented with 1ug purified GST-VHL protein for 2 hours at room 
temperature. Samples were centrifuged at 8000xg for 30 seconds and washed 
three times with PBS and re-suspended with 40ul ADBI (assay dilution buffer i) 
(20mM MOPS, ph7.2, 25mM beta-glycerol phosphate, 5mM EGTA, 1mM sodium 
orthovanadate, 1mM dithiothreitol) supplemented with 10ul Mg2+/ATP cocktail 
(75mM magnesium chloride and 500uM ATP in ADBI) and 200ng purified P-ERK 
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(14-173 Merck Millipore). The phosphorylation assay (MAP Kinase/Erk Assay, 
non-radioactive, 17-191 Merck Millipore) was processed for 30 minutes at room 
temperature with rotation at 30°C. Samples were centrifuged at 8000xg for 30 
seconds and washed three times with PBS and eluted with 30ul Laemmli buffer, 
boiled for 5 minutes and centrifuged at 8000xg for 30 seconds. Eluted 
supernatant was analyzed by immunoblot using phosphor specific BIM antibody 
(p-Ser69 (D7E11). 
 
BIM-EL Half-life  
786-0 cells were cultured in 6-well plates in 2 ml DMEM medium to reach 50% 
confluency. Cells were treated with 10 uM cyclohexamide at the indicated times, 
harvested and lysed in 150ul EBC lysis buffer. Lysates were analyzed by 
immunoblotting with rabbit anti-BIM-EL antibody. Image J Densitometry analysis 
was performed to quantify BIM-EL expression and determine protein half-life. 
 
Statistics 
Statistical analyses were performed when appropriate and P values indicated by 
an asterisk in the figure legends. Significant differences between means for 
multiple comparison analyses were conducted using ANOVA, followed by 
Bonferroni correction for post hoc analysis.  
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FIGURE LEGENDS 
Figure 1. EglN3 regulation of BIM-EL protein is hydroxylation dependent. 
(A) Photographs of dissected mouse superior cervical ganglia (SCG) of the 
indicated genotype and age. (B) Anti-BIM-EL immunoblot of dissected superior 
cervical ganglion (SCG) from 1 week old mice of the indicated genotype. (C) 
Anti-BIM-EL immunoblot of primary EglN3-MEFs of indicated genotype. (D) Anti-
BIM-EL immunoblot of SK-N-FI cells that were stably transduced with lentivirus 
encoding shRNA targeting EglN3 (shEglN3) or scramble control (shSCR). (E) 
Immunoblot analysis of EglN3-MEFs transduced with adenovirus encoding either 
wild-type EglN3, catalytic-dead mutant (H196A) or GFP-control (GFP). (F) Anti-
BIM-EL immunoblot analysis of HeLa cells transfected with siRNA targeting 
EglN1, EglN2, EglN3 or non-targeting control (SCR) as indicated. (G) 
Immunoblot and crystal violet staining of U87 cells transduced with adenovirus 
encoding wild-type EglN3, catalytic dead mutant (H196A) or GFP-control (Ctr). 
48h post-adenovirus transduction, cells were supplemented with medium and 
maintained in culture for one additional week, followed by crystal violet staining. 
(H) Immunoblot of EglN3 primary MEF’s with indicated genotype upon normoxic 
or anoxic conditions for 16h or treated with 1mM DMOG or 50uM FG0041. (I) 
Left panel: Crystal violet staining of U87 cells stably transduced with lentiviral 
pLKO shRNA targeting BIM (shBIM) or non-targeting control (shSCR) and 
subsequently transiently transduced for 48 hrs with adenovirus encoding EglN3 
or GFP-control. The corresponding immunoblot is shown in the right panel. 
Figure 2. BIM-EL protein regulation by EglN3 is depending upon pVHL. 
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(A) Anti-BIM-EL immunoblot of VHL+/+ and VHLfl/fl MEFs (immortalized by K1 
large T antigen) that were transiently transduced with adenovirus encoding cre-
recombinase or GFP-control. (B) Anti-BIM-EL immunoblot analysis of 786-O VHL 
null cells (-/-) stably transfected to generate wild-type VHL (WT). (C) Immunoblot 
of 786-O cells with indicated VHL status transduced with lentiviral pLKO shRNA 
targeting EglN3 or non-targeting control (shSCR). (D) Immunoblot of 786-O WT-
VHL (WT) and VHL null cells (-/-) under normoxic or anoxic conditions for 16h. (E) 
Immunoblot of 786-O cells stably transfected to generate the indicated VHL 
species. (F) Crystal violet staining (left) of 786-O cells with indicated VHL status. 
Cells were transiently transduced for 48hr with adenovirus encoding either wild-
type EglN3 or GFP-control. Cells were maintained in culture for an additional 
week, before being subjected to crystal violet staining. The corresponding 
immunoblot (right) is shown 48h after infection. (G) Crystal violet staining and 
immunoblot of 786-O cells expressing HA-VHL that were stably transduced with 
lentiviral-encoded shRNA targeting BIM (shBIM) or non-targeting control 
(shSCR). Cells were transiently transduced with adenovirus encoding EglN3 or 
GFP-control. (H) Immunoblot analysis of stable polyclonal PC12 cells expressing 
the indicated human VHL species. PC12 clones were transiently transduced for 
72 hours with lentivirus encoding shRNA targeting endogenous ratVHL (sh-rVHL) 
or scramble control (sh-SCR). Note: VHL long term knockdown was not tolerated 
in PC12 cells. (I) Percentage of fragmented nuclei of stable PC12 clones 3 days 
after co-transfection to generate GFP-histone and Flag-EglN3 along with pLKO 
plasmid targeting ratVHL (sh-rVHL) or scramble control (shSCR). One way 
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ANOVA was used to determine the statistical significance using Prism software 
????p<0.0001. (J) Anti-BIM-EL immunoblot analysis of human normal adrenal 
glands and human primary pheochromocytoma (PCC) and paraganglioma (PGL) 
tumors. VHL mutation and 1p36 status have been characterized as indicated. 
 
Figure 3. BIM-EL is hydroxylated by EglN3 at Proline 67/70 causing pVHL 
recognition. 
(A) Autoradiograms showing recovery of 35S-labeled EglN1, EglN2, EglN3, 
proteins bound to GST-BIM-EL or GST-BIM-L fusion proteins (GST protein as a 
negative control). 35S labeling was carried out by in vitro translation reaction with 
retic lysate (IVT). (B) Autoradiograms showing recovery of 35S-labeled VHL 
protein bound to HA-immunoprecipitated full length BIM-EL, BIM-L or HIF1? that 
were first subjected before to hydroxylation by EglN3 wild-type (WT). IgG served 
as negative control. 35S labeling was carried out by IVT with retic lysate. EglN3, 
BIM-EL, BIM-L or HIF1? were produced by cold IVT. Flag-EglN3 expression was 
verified by immunoblot (5% input). (C) Immunoprecipitation using anti-
hydroxyproline antibody (a-HydroxyP) from 293T cells that were transiently 
transfected with plasmids encoding HA-BIM-EL apoptotic mutant (∆BH3) and 
Flag-EglN3 wild-type (WT) or catalytic-dead mutant (Mut). Immunoblots showing 
co-immunoprecipitation of HA-BIM-EL-∆BH3. (D) Schematic representation of 
the various biotinylated synthetic BIM-EL peptides used for the EglN3 binding 
and hydroxylation assays. (E) Autoradiograms showing recovery of 35S-labeled 
VHL protein bound to biotinylated BIM-EL-peptide-57-96 or HIF1? peptide-556–
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575.  Prior to pull-down, peptides were incubated with either EglN1, EglN2, 
EglN3 or EglN3 catalytic mutant (Mut) generated by IVT or unprogrammed 
reticulocyte lysate (-). Expression of IVT-produced EglN proteins in each reaction 
was verified by immunoblot. (F) Mass spectrometry of biotinylated BIM-EL-
peptide subjected to EglN3 hydroxylation assay. Representative fragmentation 
spectra of hydroxylated Biotin-HGSPQGPLAPP(ox)ASP(ox)GP.  (G) 
Hydroxylation levels of proline residue 67 and 70 of BIM-EL peptide (mono- or 
double hydroxylation are indicated as mono-HyP and 2HyP) following 
hydroxylation with EglN3 wild-type (wt) or catalytic mutant generated via IVT. The 
detected intensity of each hydroxylated peptide was normalized to the non-
hydroxylated peptide. (H) Autoradiograms of EglN3 hydroxylation and S35-VHL 
capture as shown in (E) using biotinylated BIM-EL peptides containing proline to 
alanine substitutions, or no substitution (WT). (I) A schematic illustration of 
synthetic biotinylated BIM-EL-peptides, unmodified (WT), or hydroxylated at P-
OH-67, P-OH-70 and P-OH-67/70. (J) Autoradiograms showing recovery of 35S-
labeled VHL protein bound to biotinylated BIM-EL peptides with indicated 
hydroxyl-prolines as outlined in I. Synthetic biotinylated HIF1? peptide (residues 
556–575) with hydroxylated proline 564 (HIF1?-P-OH) was included as a control. 
Unmodified peptide is indicated as BIM-EL-WT. 
 
Figure 4. VHL disease mutations fail to recognize proline hydroxylated BIM-
EL. 
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(A) Autoradiograms showing recovery of 35S-labeled VHL protein (WT) or 
corresponding disease mutants (as indicated) bound to biotinylated BIM-EL-
peptides synthesized with double hydroxyl-prolines on proline 67 and 70 (BIM-
EL-P-OH-67/70). Synthetic biotinylated HIF1? peptide (residues 556–575) with 
hydroxylated proline 564 (HIF1?-P-OH) was included as a control. An un-
programmed IVT was used as a negative control. (B) Immunoblot of HA-VHL 
pull-down using biotinylated BIM-EL-P-OH-67/70-peptide or unmodified BIM-EL 
peptide (WT) or control peptide (scramble) incubated with whole cell lysate from 
786-O HA-VHL expressing cells. (C) Peptide pulldown as shown in (B) using 
either biotinylated BIM-EL-P-OH-67/70-peptide or biotinylated HIF1?P-OH 
peptide incubated with whole cell lysates from 786-O cells expressing either HA-
VHL wild-type (WT) or HA-VHL disease mutants. (D) Immunoblot analysis of 
endogenous BIM-EL and HIF2? protein expression in 786-O cells expressing 
either HA-VHL wild-type (WT) or HA-VHL disease mutants. 
 
Figure 5. VHL regulates BIM-EL protein stability depending on EglN3 
enzymatic activity. 
(A) Immunoblot of EglN3-MEFs with indicated genotype treated for 6h with 
proteasomal inhibitor MG132 (10uM) or DMSO. (B) Immunoblot of 786-O VHL 
null cells (-/-) or stably cells transfected to generate wild-type HA-VHL (WT) 
treated for 6h with proteasomal inhibitor MG132 (10uM) or DMSO as control. (C) 
Anti-phospho-BIM-EL(Ser69) immunoblot analysis of whole cell lysates from 
EglN3 MEFs with indicated genotype (D) Anti-phospho-BIM-EL(Ser69) 
immunoblot of whole cell lysates derived from VHL MEFs with indicated 
 36 
genotype transduced with lentivirus encoding either cre-recombinase or empty 
control lentivirus. (E) HA-VHL immunoprecipitation from 786-O cells transduced 
with lentivirus encoding shRNA targeting EglN3 (shE3) or scramble control 
(SCR). Immunoblots showing co-immunoprecipitation of endogenous BIM-EL 
and HA-VHL expression. (F) HA-VHL immunoprecipitation from 786-O cells with 
stable expression of either HA-VHL wild-type (WT) or HA-VHL type 2C mutant 
(L188V). VHL-null cells (-/-) served as negative control. Immunoblots showing co-
immunoprecipitation of endogenous BIM-EL and HA-VHL expression. (G) ERK-
kinase activity measured by using wild-type BIM-EL-peptide (WT) or 
hydroxylated peptide BIM-EL-P-OH-67/70 as substrates. Peptides were 
incubated with purified active ERK as indicated and kinase activity was 
measured by phospho-BIM-EL(Ser69) immunoblot analysis. (H) ERK-kinase 
activity was measured as in (G) using hydroxylated BIM-EL-P-OH-67/70 peptide. 
Prior to ERK-kinase reaction, the peptide was incubated with purified GST-VHL 
as indicated. Shown is the immunoblot of phospho-BIM-EL(Ser69) peptide 
indicating that the presence of VHL prevent substrate recognition and 
phosphorylation by ERK. (I) 786-O VHL-null cells (-/-) or stable HA-VHL wild-type 
(WT) expressing cells were treated with 10?g/ml cycloheximide (CHX). At the 
indicated time points, whole-cell lysates were prepared for immunoblot analysis. 
(J) Quantification of the band intensities in (I). (K) EglN3 MEFs with indicated 
genotype were treated with cycloheximide (CHX) at the concentration of 10?g/ml 
and whole-cell lysates were prepared for immunoblot analysis at the indicated 
time points. (L) Quantification of the band intensities in (K). (M) Immunoblot of 
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786-O VHL-null (-/-) cells co-transfected with HA-VHL together with apoptotic 
defective HA-BIM-EL-∆BH3 (indicated as “WT”) or HA-BIM-EL-∆BH3-S69A 
mutant. (N) Immunoblot of 786-0 VHL-/- cells that were transiently transfected 
with plasmids encoding apoptotic defective HA-BIM-EL-∆BH3 and HA-VHL as 
indicated. 24 hrs after transfection, cells were respectively treated for 24 hrs with 
different ERK-kinase inhibitors SCH772984 (1uM), Ulixertinib (1uM), U0126 
(10uM). 
 
Figure 6. Loss of EglN3 or VHL contributes to Cisplatin drug resistance.  
(A) Expression levels of EglN3, as represented by RPKM values, in human high-
grade glioblastoma cells (JM3, JM2, KS1, KS4, KS8, G3) and human U87 glioma 
cell line. Data are shown as mean ?SEM. ***, p<0.001. (B) Crystal violet staining 
and immunoblot analysis of human glioblastoma cells JM3 (EglN3 positive) and 
KS4 (EglN3 negative) cells treated with Cisplatin (5uM) for 48h. For crystal violet 
staining, cells were maintained in culture for additional 5 days. Immunoblot 
analysis was performed 48h post-cisplatin treatment. (C) Crystal violet staining 
and immunoblot analysis of KS4 cells stably transduced with lentivirus encoding 
Flag-EglN3 wild-type (WT), catalytic dead mutant (H196A) or empty control. 
Stable clones were treated with cisplatin (5uM) as indicated. Immunoblot was 
performed 48h post-Cisplatin treatment. For crystal violet staining, cells were 
maintained for additional 5 days in culture. (D) Crystal violet staining and 
immunoblot analysis of 786-O cells with indicated VHL status. Cells were treated 
with cisplatin once (5uM). Immunoblot was performed 72h post-cisplatin 
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treatment. For crystal violet staining, cells were maintained in culture for 
additional 4 days. (E-F) Crystal violet staining of KS4 stably transduced cells as 
(C) and treated once with cisplatin (5uM), Erk inhibitor SCH772984 (SCH 5uM) 
or combination of these two drugs as indicated. For crystal violet staining, cells 
were maintained for one week. Corresponding immunoblot shown in (F) 48 hrs 
post treatment. (G-H) Crystal violet staining (G) and corresponding immunoblot 
(H) of stable 786-O cells treated once with cisplatin (5uM), ERK-inhibitor 
SCH772984 (SCH 1uM) or combination of both as indicated for 72 h. For crystal 
violet staining, cells were maintained for 7 days.  
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